Monday, October 04, 2021 11:46:46 AM
William Blair Raises Price Target From $30 To $46; Raises Probability Of Success For XEN1101 In FOS From 60% To 85%
XENE
XENE
New York Yankees and Duke Basketball
Recent XENE News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:16:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:16:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2026 12:16:26 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/13/2026 11:51:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/13/2026 11:50:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/13/2026 11:49:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:10:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:17:51 PM
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares • GlobeNewswire Inc. • 03/12/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 11:21:20 PM
- Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering • GlobeNewswire Inc. • 03/11/2026 02:39:32 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2026 01:01:40 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/09/2026 08:54:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/09/2026 08:46:22 PM
- Xenon Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results • IH Market News • 03/09/2026 02:16:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 11:36:58 AM
- Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) • GlobeNewswire Inc. • 03/09/2026 11:00:00 AM
- Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 • GlobeNewswire Inc. • 03/08/2026 06:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:03:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2026 09:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:03:12 PM
